We report a case of an 11-year-old boy who underwent successful bone marrow transplantation for X-linked hyper-IgM syndrome (XHIM). The donor was an HLAmatched brother. The patient was conditioned with busulfan, cyclophosphamide and anti-thymocyte globulin. He received 4.7 ؋ 10 8 marrow cells per kg from the donor. Prophylaxis against graft-versus-host disease consisted of cyclosporine and short-term methotrexate. The clinical course after the bone marrow transplantation was uneventful, and 12 months after transplantation the patient was doing well with no need for therapy. We examined expression of the CD40 ligand (CD40L) on the patient's activated T lymphocytes and in vitro production of immunoglobulins by his lymphocytes. Although expression of CD40L was totally absent before the bone marrow transplant, subnormal expression appeared after the transplantation. In vitro production of IgG and IgA also was improved by the transplant. Based on our experience bone marrow transplantation appears to be a reasonable therapeutic option for patients with XHIM if HLA-matched family donors are available. Keywords: X-linked hyper-IgM syndrome; CD40 ligand; bone marrow transplantation X-linked hyper-IgM (XHIM) syndrome is a rare genetic disorder characterized by recurrent infections associated with markedly decreased serum IgG, IgA, and IgE levels, and normal to increased levels of serum IgM.
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In 1993 several groups of researchers demonstrated that this disease is caused by mutations of the CD40 ligand (CD40L) gene located at Xq26.3-27.1. [2] [3] [4] [5] [6] The CD40L gene encodes a 33 kDa type II membrane glycoprotein expressed on activated T lymphocytes. 7, 8 The interaction of the CD40 molecule on B lymphocytes with the CD40L on activated T lymphocytes results in immunoglobulin class switching. 7 Correspondence: Dr S Kojima, Division of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya 453-8511, Japan Received 19 August 1998; accepted 26 November 1998 T lymphocyte function is compromised, resulting in recurrent opportunistic infections with Pneumocystis carinii, Cryptosporidium and so on. 1, 9, 10 Neutropenia is also commonly associated with this disease. 1 Therapy over the past decade has included the use of intravenous ␥-globulin and cytokines such as G-CSF. 1, 10 In 1995 Thomas et al 11 first reported bone marrow transplantation in a child with XHIM from an HLA-matched sister. After transplantation, expression of CD40L on the recipient's T lymphocytes became equivalent to that on the donor's T lymphocytes, and the patient had a full recovery of immune function. Several patients have subsequently been treated by bone marrow transplantation, 12 but detailed information concerning clinical course and immunologic studies are lacking.
We performed a bone marrow transplant on a patient with XHIM using donor cells from an HLA-matched brother. We report the clinical course of this patient and the results of immunologic studies performed before and after the transplant.
Case report
A 5-month-old boy was admitted to our hospital because of Pneumocystis carinii pneumonitis. He required mechanical ventilatory support and recovered with the administration of trimethoprim-sulfamethoxazole. His maternal uncle had died of pneumonia at the age of 8 months and was suspected to have XHIM. At the time of first admission, laboratory studies revealed low levels of serum IgG (Ͻ36 mg/dl) and IgA (7 mg/dl), but the serum IgM level (112 mg/dl) was normal for his age. A diagnosis of XHIM was made on the basis of the following immunologic studies: the number of T lymphocytes and the ratio of CD4 + T lymphocytes to CD8 + T lymphocytes were normal. The number of surface IgM positive B lymphocytes was increased, while surface IgG positive lymphocytes were decreased. In vitro proliferative responses to PHA, ConA, pokeweed mitogen (PWM), and Staphylococcus aureus Cowan I(SAC) were normal. Autoantibodies were not demonstrated. Recently, the diagnosis of XHIM has been confirmed by the finding that the expression of CD40L on his activated T lymphocytes was diminished. Nucleotide sequence analysis revealed a deletion at nucleotide 655.
This deletion leads to a truncation in the extracellular domain of CD40L with the introduction of the premature stop codon owing to a frameshift. After the first hospitalization, the patient received intravenous immunoglobulin every 2 weeks and prophylactic trimethoprim-sulfamethoxazole. At the age of 5 years, severe neutropenia was demonstrated during an exacerbation of chronic esophagitis. The patient was subsequently treated with G-CSF at the times of severe infection. In spite of prophylaxis he had repeated episodes of bacterial infections such as otitis media and bronchiolitis. However, he had no clinical signs of cryptosporidosis such as prolonged diarrhea and hepatobiliary disease.
After a series of opportunistic infections, the parents gave informed consent for their 11-year-old son to undergo a bone marrow transplant. The donor was his 7-year-old HLA-identical brother. The patient's blood type was Apositive and the donor's was B-positive.
The patient was conditioned with busulfan (4 mg per kg) from days Ϫ9 to Ϫ6, cyclophosphamide (50 mg per kg) from days Ϫ5 to Ϫ2, and anti-thymocyte globulin (Lymphoglobulin, Pasteur Mérieux, Lyon, France, 15 mg per kg) from days Ϫ5 to Ϫ2. Graft-versus-host disease prophylaxis consisted of short-term methotrexate (15 mg per m 2 on day 1 and 10 mg per m 2 on days 3, 6 and 11) and cyclosporine (3 mg per kg per day as an intravenous infusion from day Ϫ1, and 6 mg per kg per day as an oral administration from day 32). Infection prophylaxis included oral administration of sulfamethoxazole-trimethoprim, amphotericin B, polymyxin B sulfate, and acyclovir, and weekly intravenous immunoglobulin (150 mg per kg).
On 24 January 1997, the patient received 4.7 ϫ 10 8 nucleated marrow cells per kg which were depleted of red blood cells. He commenced G-CSF on day 6. The clinical course after the bone marrow transplant was uneventful. The absolute neutrophil count exceeded 0.5 ϫ 10 9 /l on day 14 and remained above 1.0 ϫ 10 9 /l after cessation of G-CSF. The last platelet transfusion was given on day 32. Engraftment was confirmed by the change of the recipient blood type from A-positive to B-positive. Neither acute nor chronic GVHD were observed, and no serious infectious complications occurred.
The patient received intravenous immunoglobulin (150 mg per kg) every week until day 188. The serum IgA level started to increase after the bone marrow transplant, normalizing on day 18. However, the serum IgM level gradually decreased. Normal concentrations of serum immunoglobulin were observed after cessation of intravenous immunoglobulin therapy (IgG, 1040 mg/dl; IgA, 90 mg/dl; IgM, 250 mg/dl).
Materials and methods

Expression of CD40L on lymphocytes
Mononuclear cells were isolated from heparinized venous blood by density gradient centrifugation on Ficoll-Paque. The cells were cultured for 12 h in the presence or absence of phorbol myristate acetate (PMA, 10 ng/ml) and Ca 2+ ionophore (2.5 g/ml). Cells were then stained with FITC- Figure 1 Expression of CD40L by activated T lymphocytes from a control subject and the patient before and after the bone marrow transplantation.
conjugated anti-CD40L (Ancell, Bayport, MN, USA) and analyzed by flow cytometry (EPICS XL, Coulter, Hialeah, FL, USA).
Assay for immunoglobulin secretion
Mononuclear cells were isolated as above. The cells were cultured for 10 days in the presence of SAC (final dilution 1:10 000) and IL-2 (100 U/ml, Shionogi, Osaka, Japan). Synthesis of IgG, IgA and IgM was measured in the supernatants by enzyme-linked immunosorbent assay.
Results
Expression of CD40L on activated T lymphocytes was defective before the bone marrow transplant. On day 49 it was identifiable. On day 186 the expression had increased further but was still less than that of the normal control (Figure 1) .
Before the bone marrow transplant in vitro secretion of IgG and IgA from the patient's lymphocytes was not observed, while IgM production was increased compared with the normal control. After the transplant the production of IgM decreased and IgG and IgA appeared (Figure 2) . 
Discussion
The pathogenesis of XHIM was thought to lie within the B lymphocytes and its inability to 'switch' in immunoglobulin class from IgM to IgG or IgA. Until recently, intravenous immunoglobulin therapy has been the treatment of choice in patients with XHIM, and some patients have received G-CSF for chronic neutropenia. None of these treatments are curative. 1, 10 Recent studies have shown that immunoglobulin class switching is mediated by the interaction of CD40L on activated T lymphocytes with CD40 on the surface of B lymphocytes, and that CD40L gene mutations cause XHIM. [2] [3] [4] [5] [6] Based on these findings, allogeneic bone marrow transplantation has become the treatment of choice for XHIM. In 1995 Thomas et al 11 have reported the first allogeneic bone marrow transplant with donor cells from an HLA-matched sister. Although the donor was a carrier of this disease and had reduced expression of CD40L on T lymphocytes, the patient had full recovery of immune function after the transplant.
Similar to the approach of Thomas et al, 11 we used busulfan and cyclophosphamide for conditioning in our patient. Full engraftment was demonstrated by the changes in red blood cell type and the expression of CD40L on activated T lymphocytes. In accordance with regimens used in other metabolic diseases and immunodeficiencies, 13,14 a conditioning regimen without irradiation appears to be preferable with regard to reducing the risk of long-term sequelae.
In our patient, expression of CD40L was shown on day 49 and day 186 after the transplant. The percentage of CD40L-positive cells in the patient was reduced compared to healthy controls. In the patient reported by Thomas et al, 11 expression of CD40L was reduced because the donor was a carrier of the same disease. Although our patient was transplanted from a healthy donor, CD40L expression was also reduced after the transplant. The reduced expression of CD40L could be the consequence of mixed chimerism or incomplete T cell ability to express CD40L. Unfortunately, his status of mixed chimerism was not studied by a sensitive method such as PCR targeting VNTR loci. Because cyclosporin is known to inhibit CD40L expression on activated T lymphocytes, 15 one of the reasons for the reduced expression may have been the on-going cyclosporin therapy at the time of the study.
However, the production of immunoglobulin normalized after bone marrow transplantation, suggesting that a reduced number of T lymphocytes which express CD40L are sufficient to provide signals for immunoglobulin class switching.
A survey of the bone marrow transplant literature for immunodeficiency disease included six patients with hyperIgM immunodeficiency. 12 One of two patients transplanted from an HLA-matched donor and one of three patients transplanted from a haplo-identical donor were long-term survivors. However, detailed information concerning clinical course and immunologic studies were not reported.
A recent report from the registry of the European Society for Immune Deficiency suggests that patients with defects in CD40L have a poor prognosis. 10 Thirteen of 56 patients have died of various causes, including severe infections, liver disease, and malignancies. There was a marked drop in survival for patients more than 10 years of age. KaplanMeier survival curves showed that only 20% of patients were alive at 25 years of age. These data suggest that bone marrow transplantation is a reasonable therapeutic choice if HLA-matched family donors are available. However, some patients with XHIM do not suffer from life-threatening infections if intravenous immunoglobulin is administered regularly. 1 Further studies may help to identify factors that predict poor outcome, allowing us to use bone marrow transplantation for the subset of patients who will benefit most.
